RR MedSciences has advanced a novel analgesic leveraging its patented small molecule drug RM191A, for the treatment of neuropathic pain. This innovative pain relief treatment is non-addictive, non-opioid and formulated as a topical medicine.
Neuropathic (nerve) pain is a condition of unmet need globally, lacking fully effective, safe medications. This life altering condition stems from a variety of causes. Neuropathic pain may occur as the result of surgery, trauma, HIV, diabetes and chemotherapy and is experienced commonly by cancer survivors.
Neuropathic pain is often chronic and does not respond effectively to current treatments. The high levels of chronic pain and discomfort results in a profound cost to personal wellbeing.
RR MedSciences' neuropathic pain candidate, RM191A in a novel gel formulation, has recently completed a Phase 2a Clinical Trial. The study was conducted at the Pain Management Research Centre at the Kolling Institute, Royal North Shore Hospital, Sydney Australia (CT Ref No: HREC/16/HAWKE/483; ACTRN12617000206325).
The gold standard, double blind, placebo controlled, randomised crossover trial tested the effectiveness of RM191A topical gel in combination with the participants current pain regimens. Participants of the trial had experienced severe neuropathic pain for more than 3 months on existing medications.
RR MedSciences anticipates the results of this trial to be published soon.